Marinus Pharmaceuticals, Inc. - Special Call Transcript
Greetings. Welcome to Marinus Pharmaceuticals RSE Phase II Data Call. (Operator Instructions) Please note, this conference is being recorded. At this time, I will turn the conference over to Lisa Caperelli, Executive Director, Investor and Strategic Relations. Lisa, you may now begin.
Thanks, Rob. Good morning, everyone, and thank you for joining this conference call, where we will review data from our Phase II clinical study evaluating intravenous ganaxolone in patients with refractory status epilepticus.
Participation on to -- participants on today's call are Dr. Scott Braunstein, CEO of Marinus; Dr. Lorianne Masuoka, our Chief Medical Officer; TJ Lyons, Vice President of Corporate and Business Development and Commercial Planning; and Dr. Henri Vaitkevicius, an investigator in this study. Available for the Q&A session will be Dr. Maciej Gasior, Executive Director of Clinical Development; and Edward Smith, our CFO.
Before we begin,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |